Skip to main content

HomeResearchGonadorelin

Educational research tools — not medical advice.

CategorySexual Health
SafetyLow Risk
RegulatoryNot Evaluated
StatusCompoundable

Gonadorelin

GnRH · Luteinizing Hormone-Releasing Hormone · LHRH

CategorySexual Health
Half-life~2-4 minutes
Routesubcutaneous, intravenous
RiskLow Risk
Providers25 listed#5 in Sexual Health

In brief

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When…

Low Risk25 providers listed

About Gonadorelin

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Gonadorelin Benefits & Research Areas

pulsatile LH and FSH stimulation from the pituitarytesticular function and testosterone production maintenancefertility preservation alongside TRT (FSH pathway intact)hypothalamic-pituitary axis restoration in hypogonadism

Research Signals

Commonly researched in the context of

Hormonal Changes

Population research notes

18–2930s40s50+

These signals reflect research interest areas, not treatment indications.

Regulatory & Evidence

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.

Regulatory Status

Availability Status
Compoundable
FDA Status
Not Evaluated

Previously FDA-approved as Factrel (NDA 017019). Voluntarily discontinued by manufacturer. On FDA 503A Category 1 bulk drug substances list for compounding. Prescription compounded product.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

3 sources cited · 3 moderate

1 Meta-analysis · 2 Cohorts

  • Effect of post-insemination GnRH analogue administration on pregnancy rates in repeat-breeder cows: comparison of dosage and frequency.

    J Reprod Dev · 2026

    # Summary Research found that administering a GnRH analogue (dephereline) during the early luteal phase after insemination improved pregnancy outcomes in repeat-breeder cows by significantly increasing corpus luteum formation and reducing pregnancy loss compared to control animals. This study demonstrated that both elevated-dose treatment protocols were similarly effective at enhancing pregnancy maintenance in this subfertile population.

    CohortModeratePMID 42091524
  • Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism: a retrospective study

    Translational Andrology and Urology · 2025

    In a retrospective cohort of 54 adult males with congenital hypogonadotropic hypogonadism, pulsatile gonadorelin (GnRH) pump treatment produced significant increases in testicular volume, serum testosterone, and penile length at 6, 12, and 24 months; 27 of 45 patients followed beyond 6 months produced spermatozoa, with better outcomes in younger patients and those with normal olfaction.

    Cohortn=54ModeratePMID 40800099
  • Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis

    Fertility and Sterility · 2018

    This systematic review and meta-analysis of 35 studies encompassing 1,002 women with hypothalamic amenorrhea found that pulsatile gonadorelin (GnRH) treatment achieved high ovulation rates with a trend toward high pregnancy and live birth rates, low OHSS incidence, and low multiple gestation rates, establishing it as an effective and safe first-line ovulation induction strategy.

    Meta-analysisn=1,002ModeratePMID 29605411

Gonadorelin Side Effects & Safety Considerations

Low Risk

Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.

Reported contraindications & considerations

Hormone-Sensitive CancersContinuous High-Dose (Causes Receptor Downregulation)

Common monitoring markers in research protocols

Standard reproductive endocrinology panels establish HPG axis baseline. LH and FSH confirm pituitary response to gonadorelin; testosterone, E2, and SHBG reflect downstream gonadal output.

Total testosteroneLHFSHEstradiol (E2)SHBGProlactin

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Research Stacks

Browse all →

Where to Buy Gonadorelin — Providers & Availability

25 providers
14 Clinics2 Pharmacys1 Online Vendor25 in stock

Stay updated on verified Gonadorelin providers

New verified providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Questions to Ask Your Provider

Frequently Asked Questions — Gonadorelin

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism.

pulsatile LH and FSH stimulation from the pituitary, testicular function and testosterone production maintenance, fertility preservation alongside TRT (FSH pathway intact), hypothalamic-pituitary axis restoration in hypogonadism.

Research on Gonadorelin primarily documents effects related to pulsatile LH and FSH stimulation from the pituitary and testicular function and testosterone production maintenance and fertility preservation alongside TRT (FSH pathway intact) and hypothalamic-pituitary axis restoration in hypogonadism. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for Gonadorelin include hormone-sensitive cancers, continuous high-dose (causes receptor downregulation). This is educational information only — consult a qualified healthcare professional before use.

25 providers in the directory currently offer Gonadorelin.

# Summary Research found that administering a GnRH analogue (dephereline) during the early luteal phase after insemination improved pregnancy outcomes in repeat-breeder cows by significantly increasing corpus luteum formation and reducing pregnancy loss compared to control animals. This study demonstrated that both elevated-dose treatment protocols were similarly effective at enhancing pregnancy maintenance in this subfertile population.

Gonadorelin is featured in the following research stacks on PeptideBase: Melanotan II + Gonadorelin: Central & Hormonal Sexual Health.

Last updated

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.